Slow-release prepn. contg. alpha-lipoic acid or its derivatives, and preparing method therefor
A sustained-release preparation, lipoic acid technology, applied in the field of biomedicine, can solve problems affecting biological activity and achieve the effect of prolonged and sustained release
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0045]The prescription of the double-layer sustained-release tablet whose main ingredient is R-(+)-α-lipoic acid is:
[0046] Sustained-release drug raw material components and content are:
[0047] R-(+)-alpha-lipoic acid 200 mg
[0048] Lactose 10mg
[0049] Hydroxypropyl Methyl Cellulose 125 mg
[0050] Ethylcellulose 20 mg
[0051] 1.5% hydroxypropyl methylcellulose solution 40 mg
[0052] Talc 5 mg
[0054] The components and content of the raw material of the long-release drug are:
[0055] R-(+)-alpha-lipoic acid 100 mg
[0056] Starch 10 mg
[0057] 6% polyvinylpyrrolidone solution 10 mg
[0058] Talc 2 mg
[0060] The film coat composition and content of this double-layer sustained-release tablet are:
[0061] Hydroxypropyl Methyl Cellulose 4 mg
[0062] Macrogol 400 6 mg
[0063] Titanium dioxide 0.5 mg
[0064] Talc 1mg
[0065] 80ml food grade ethanol
[0066] water 20ml
[0067] The ...
Embodiment 2
[0079] The main ingredient is S-(-)-α-lipoic acid The prescription of the double-layer sustained-release tablet is:
[0080] Sustained-release drug raw material components and content are:
[0081] S-(-)-alpha-lipoic acid 250 mg
[0082] Lactose 10mg
[0083] Hydroxypropyl Methyl Cellulose 125 mg
[0084] Ethylcellulose 20 mg
[0085] 1.5% hydroxypropyl methylcellulose solution 40 mg
[0086] Talc 5mg
[0088] The components and content of the raw material of the long-release drug are:
[0089] S-(-)-alpha-lipoic acid 50 mg
[0090] Starch 10 mg
[0091] 6% polyvinylpyrrolidone solution 10 mg
[0092] Talc 2 mg
[0093] Magnesium stearate 2mg
[0094] The film coat composition and content of this double-layer sustained-release tablet are:
[0095] Hydroxypropyl Methyl Cellulose 4mg
[0096] Macrogol 400 6 mg
[0097] Titanium dioxide 0.5 mg
[0098] Talc 1mg
[0099] 80ml food grade ethanol
[0100] water 20ml
[0101] The prep...
Embodiment 3
[0113] The prescription of sustained-release tablets whose main drug is a mixture of R-(+)-α-lipoic acid and S-(-)-α-lipoic acid is:
[0114] Blend of R-(+)-alpha-lipoic acid and S-(-)-alpha-lipoic acid 300mg
[0115] Lactose 10mg
[0116]Hydroxypropyl Methyl Cellulose 125 mg
[0117] Ethylcellulose 20 mg
[0118] 1.5% hydroxypropyl methylcellulose solution 40 mg
[0119] Talc 5mg
[0120] Magnesium stearate 2mg
[0121] The film coat component and content of this layer sustained-release tablet are:
[0122] Hydroxypropyl Methyl Cellulose 4mg
[0123] Macrogol 400 6 mg
[0124] Titanium dioxide 0.5 mg
[0125] Talc 1mg
[0126] 80ml food grade ethanol
[0127] water 20ml
[0128] The preparation process of this slow-release tablet is as follows:
[0129] Mixture of R-(+)-α-lipoic acid and S-(-)-α-lipoic acid, starch, hydroxypropylmethylcellulose, ethylcellulose, microcrystalline cellulose, sodium starch glycolate According to the composition and content of the pre...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More - R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com
